Zelgen Pharmaceutical daim ntawv thov rau ib chav kawm tshiab 1 tshuaj mob siab mob siab yuav raug suav nrog hauv kev tshuaj xyuas ua ntej

Lub Kaum Hlis 12, Lub Chaw Saib Xyuas Tshuaj (CDE) ntawm Lub Xeev Tswj Xyuas Khoom Noj thiab Tshuaj ntawm Tuam Tshoj tau tshaj tawm cov lus tshaj tawm tshiab ntawm lub vev xaib ntawm Zelgen Pharmaceutical' s Chav Kawm 1 tshuaj tshiab Donafinil tosylate ntsiav tshuaj yuav tsum tau suav nrog hauv kev tshuaj xyuas ua ntej. thiab cov cim taw qhia rau daim ntawv thov no Rau kev kho mob ntawm kev mob qib siab (tsis tuaj yeem lossis metastatic) hepatocellular carcinoma. Qhov no tsis tsuas yog txhais tau tias Donafinil xav tias yuav pom zoo sai dua nyob rau hauv Suav teb, tab sis kuj txhais tau tias Zejing Cov Tshuaj yuav tsum coj mus rau thawj cov tshuaj pom zoo.

Donafinil yog qhov ncauj ua ntau lub hom phiaj, ntau lub zog kinase inhibitor, cov tshuaj tiv thaiv qog ntshav me me tau tsim los ntawm Zejing Pharmaceutical, thiab zwm rau hauv chav kawm 1 cov tshuaj tshiab. Preclinical pharmacological cov kev tshawb fawb tau lees tias cov tshuaj muaj peev xwm inhibit qhov kev ua ntawm ntau yam receptor tyrosine kinases xws li VEGFR thiab PDGFR, thiab tseem tuaj yeem cuam tshuam ncaj qha rau ntau yam Raf kinases, thiab inhibit qhov dej ntws qis Raf / MEK / ERK cov paib. Kev loj hlob ntawm cov qog hlwb thiab tsim cov qog cov hlab ntshav ua si tawm tsam cov qog ntawm ntau cov kev txwv thiab ntau lub hom phiaj thaiv.

Raws li cov xov xwm tshaj tawm los ntawm Zejing Pharmaceutical ua ntej dhau los, daim ntawv thov cov npe tshuaj tshiab no yog raws li cov txiaj ntsig ntawm kev sim ZGDH3. ZGDH3 yog kev qhib, kev xaiv, thaum sib tw, ntau lub chaw ntawm 2/3 kev soj ntsuam kev tshawb fawb, coj los ntawm cov xibfwb Qin Shukui, tus lwm thawj ntawm Tuam Thawj Koom Tes ntawm Suav Tebchaws ntawm Kev Tshawb Xyuas Oncology (CSCO), los tshawb txog kev siv Donafenib ntsiav tshuaj hauv cov neeg mob nrog qib siab hepatocellular carcinoma Ua tau kom zoo thiab muaj kev nyab xeeb rau kev kho thib ib. Thawj qhov kawg ntawm txoj kev tshawb no yog qhov muaj sia nyob tag nrho (OS), thiab qhov kawg ntawm txoj kev kawm muaj xws li kev vam meej tsis muaj kev vam meej (PFS), lub hom phiaj ntawm cov lus teb (ORR), kev tswj tus kab mob (DCR), kev nyab xeeb, thiab tiv taus.

Cov txiaj ntsig sim pom tau hais tias ZGDH3 txoj kev tshawb nrhiav tau ntsib qhov kev npaj tseg ua ntej qhov xaus thiab cov qauv ntsuas. Ntawm cov neeg mob uas tsis tuaj yeem lossis nrog cov neeg mob ua kom zoo li tus mob ua rau lub cev nqaij daim tawv nqaij uas tsis tau txais kev kho mob, qhov nruab nrab muaj txoj sia nyob (mOS) ntawm pab pawg kho mob donafenib tau zoo dua li ntawm kev tswj hwm tshuaj sorafenib kho mob pab pawg, mus txog qhov txheeb cais qhov sib txawv thiab tseem ceeb hauv chaw kho mob. Cov. Ib qho ntxiv, Donafenib pawg pom tias muaj kev nyab xeeb zoo dua qhov kev tshwm sim ntawm qib 3 thiab siab dua qhov xwm txheej tsis zoo, thiab qhov tshwm sim ntawm cov tshuaj cuam tshuam txog yeeb tshuaj uas ua rau txo kev haus tshuaj lossis txo koob tshuaj.

Raws li cov ntaub ntawv ntawm lub vev xaib ntawm Zejing Pharmaceuticals, tau tshaj tawm xyoo 2020 ntawm" Cov Lus Qhia rau Kev Tshuaj Ntsuam Xyuas thiab Kev Kho Mob ntawm Tus Mob Hnyav Qog Cancer" tawm los ntawm Suav Cov Neeg Koom Tes ntawm Kev Tshawb Nrhiav Oncology nyob rau lub Xya Hli xyoo no, Donafenib tau raug teev npe ua thawj kab kev kho rau tus mob hepatocellular carcinoma thiab yog qib kuv tus kws tshaj lij pom zoo thiab 1A pov thawj.

Nws yog tsim nyog teev tias cov ntsiab lus ntawm ZGDH3 cov kev tshawb fawb tau los kuj raug xaiv tau zoo rau qhov ncauj lus ntawm xyoo no' s American Society of Clinical Oncology (ASCO) lub rooj sib tham txhua xyoo. Raws li haiv neeg Suav ntawm Kev Kho Mob Oncology, qhov no yog thawj qhov kev tshawb fawb loj ntawm thawj txoj kev kho mob ntawm kev kho mob hepatocellular carcinoma nrog kev siv tshuaj tshiab tsim los ntawm Tuam Tshoj thiab coj los ntawm Suav cov kws tshawb fawb nyob hauv kaum xyoo dhau los. Cov txiaj ntsig thiab cov ntaub ntawv tau tshaj tawm rau lub ntiaj teb hauv lub rooj sib tham ASCO.

Ntxiv nrog rau kev mob qog noj ntshav, Zejing Pharmaceuticals tab tom ua cov kev tshawb fawb tseem ceeb hauv Donafenib hauv kev kho mob rau txoj hnyuv mob siab thiab mob qog nqaij hlav cancer, thiab tseem nquag txhawb Donafenib ua ke nrog PD-1 / PD-L1 monoclonal cov tshuaj tiv thaiv kev tshawb fawb tshiab ntawm kev kho mob ntawm ntau yam qog.